Physician profile
Rahil Patel
NPI 1811023880
$8,705.13
in general payments reported to CMS, 2019-2025
29 companies · $896 in 2025
The $896 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $1,191 · 2021: $947 · 2022: $2,073 · 2023: $1,166 · 2024: $1,340 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,387 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,386.57 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,582.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,605.92 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Medtronic, INC. | $785.98 | 2021-2023 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $537.68 | 2022-2023 | |
| Lilly USA, LLC | $423.95 | 2019-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $389.72 | 2019-2025 | Jardiance |
| Amgen INC. | $332.19 | 2022-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $288.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $281.26 | 2019-2025 | |
| Gilead Sciences, INC. | $161.02 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $159.19 | 2019-2021 | |
| Philips North America LLC | $146.56 | 2021-2022 | |
| Daiichi Sankyo INC. | $137.47 | 2021-2023 | Injectafer |
| Abbvie INC. | $125.00 | 2025 | |
| Madrigal Pharmaceuticals | $125.00 | 2025 | Rezdiffra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $98.14 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Dexcom, INC. | $83.21 | 2024 | Dexcom G7 Gss (161) |
| Abbott Laboratories | $82.81 | 2021-2024 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $69.69 | 2022-2023 | Hetlioz |
| Novartis Pharmaceuticals Corporation | $66.98 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $39.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.21 | 2020-2021 | |
| Astellas Pharma US INC | $34.82 | 2025 | Veozah |
| Mallinckrodt Hospital Products INC. | $27.99 | 2022 | |
| Sanofi-Aventis U.S. LLC | $26.19 | 2019 | |
| Sanofi Pasteur INC. | $16.77 | 2023 | |
| Althera Pharmaceuticals LLC | $15.10 | 2021 | |
| Allergan, INC. | $12.15 | 2019 | |
| Genentech USA, INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.